By Counterforce Health Team in Nucala (mepolizumab) —

How to Get Nucala (mepolizumab) Covered by Blue Cross Blue Shield in Ohio: Complete PA Guide with Appeals

Answer Box: Quick Path to Nucala Coverage in Ohio

To get Nucala (mepolizumab) covered by Blue Cross Blue Shield in Ohio: Submit prior authorization with blood eosinophil count ≥150-300 cells/μL, documentation of severe eosinophilic asthma uncontrolled on high-dose inhaled therapy, and specialist prescription. If denied, file internal appeal within 180 days, then external review through Ohio Department of Insurance. Start today: Contact your prescriber to initiate PA submission through your BCBS plan's provider portal or specialty pharmacy (verify with member services number on your insurance card).

Table of Contents

  1. Policy Overview: How BCBS Ohio Handles Nucala
  2. FDA-Approved Indications & Medical Necessity
  3. Step Therapy Requirements & Exceptions
  4. Quantity Limits & Dosing Rules
  5. Required Diagnostics & Lab Values
  6. Site of Care & Specialty Pharmacy Requirements
  7. Evidence to Support Medical Necessity
  8. Appeals Process: Internal to External Review
  9. Common Denial Reasons & How to Fix Them
  10. FAQ: Ohio-Specific Questions

Policy Overview: How BCBS Ohio Handles Nucala

Blue Cross Blue Shield operates as 33 independent plans across the United States, with Ohio served primarily by Anthem Blue Cross Blue Shield, which holds approximately 31% of Ohio's health insurance market share. While specific prior authorization criteria can vary between BCBS plans, they generally share common frameworks for specialty medications like Nucala.

Key Plan Types in Ohio:

  • Commercial (HMO/PPO): Standard PA requirements with 180-day appeal windows
  • Medicare Advantage: May have additional CMS-guided criteria
  • Medicaid Managed Care: Subject to Ohio Medicaid PA requirements
Note: Self-funded employer plans follow federal ERISA law but often use similar PA processes voluntarily.

FDA-Approved Indications & Medical Necessity

Nucala (mepolizumab) is FDA-approved for four main indications, each with specific age and clinical requirements:

Coverage at a Glance

Indication Age Requirement Key Criteria Typical Dosing
Severe Eosinophilic Asthma ≥6 years Blood eosinophils ≥150 cells/μL (screening) or ≥300 cells/μL (past year) 100 mg SC every 4 weeks (≥12 years); 40 mg SC every 4 weeks (6-11 years)
EGPA ≥12 years Eosinophilic granulomatosis with polyangiitis 300 mg SC every 4 weeks
Hypereosinophilic Syndrome (HES) ≥12 years HES with organ involvement ≥6 months 300 mg SC every 4 weeks
Chronic Rhinosinusitis with Nasal Polyps ≥18 years Add-on to standard care 100 mg SC every 4 weeks

Source: FDA Prescribing Information

Step Therapy Requirements & Exceptions

Most BCBS plans require patients to try and fail alternative treatments before approving Nucala. Based on similar BCBS policies nationwide, Ohio likely follows these patterns:

Typical Step Therapy Sequence

  1. High-dose inhaled corticosteroids (ICS) + long-acting beta agonist (LABA) for ≥3 months
  2. Triple therapy (ICS + LABA + long-acting muscarinic antagonist) for ≥90 days
  3. Alternative biologics like benralizumab (Fasenra) or dupilumab (Dupixent)

Medical Exception Pathways

You can bypass step therapy if you document:

  • Contraindications to required steps (allergies, drug interactions)
  • Previous intolerance with specific adverse events
  • Prior failure on the same medications (within reasonable timeframe)
  • Clinical urgency requiring immediate biologic therapy
Tip: Keep detailed records of all previous asthma medications, including dates, doses, duration, and reasons for discontinuation.

Quantity Limits & Dosing Rules

BCBS plans typically align quantity limits with FDA-approved dosing:

  • Severe Eosinophilic Asthma: 1 injection (100 mg) per 28 days for adults; 1 injection (40 mg) per 28 days for children 6-11 years
  • EGPA/HES: 3 injections (300 mg total) per 28 days
  • CRSwNP: 1 injection (100 mg) per 28 days

Reauthorization Requirements:

  • Initial approval: 6-12 months
  • Renewal: Requires documentation of clinical response (reduced exacerbations, improved lung function, decreased oral steroid use)

Required Diagnostics & Lab Values

Essential Lab Work

Blood Eosinophil Count Requirements:

  • Severe Eosinophilic Asthma: ≥150 cells/μL within 6 weeks of PA submission OR ≥300 cells/μL within past 12 months
  • Other indications: While not specified in FDA labeling, most payers require evidence of eosinophilic disease

Additional Documentation Needed

  • Pulmonary function tests (FEV1, FVC) showing impairment
  • Asthma Control Test (ACT) or Asthma Control Questionnaire (ACQ) scores
  • Exacerbation history: Number of severe exacerbations requiring oral corticosteroids or hospitalization in past 12 months
  • ICD-10 diagnosis codes: J45.20-J45.998 for asthma variants
Note: Labs should be recent (within 6-12 months) and from a certified laboratory.

Site of Care & Specialty Pharmacy Requirements

Based on BCBS site-of-care policies, Ohio plans likely prefer cost-effective administration sites:

Preferred Sites

  1. Home self-administration (with proper training)
  2. Physician office injection
  3. Ambulatory infusion centers
  4. Specialty pharmacy with home nursing

Hospital Outpatient Facility (HOF) Restrictions

HOF administration typically requires documentation of:

  • First dose or re-initiation after ≥6 months
  • History of hypersensitivity requiring immediate medical intervention
  • Patient instability or inability to use preferred sites

Specialty Pharmacy Process:

  1. Prescriber sends prescription to approved specialty pharmacy (often Accredo or CVS Caremark)
  2. PA approval obtained
  3. Patient training on self-injection technique
  4. Medication shipped to patient's home

Evidence to Support Medical Necessity

Clinical Guidelines to Reference

When submitting PA requests or appeals, cite these authoritative sources:

Sample Medical Necessity Paragraph

"Patient has severe persistent eosinophilic asthma (ICD-10: J45.22) with blood eosinophil count of 280 cells/μL, remains uncontrolled despite 6 months of high-dose fluticasone/salmeterol plus tiotropium, experiencing 4 exacerbations requiring oral prednisone in past 12 months. Per GINA 2023 guidelines and FDA labeling, mepolizumab is indicated for add-on maintenance in patients ≥6 years with eosinophilic phenotype and inadequate control on standard therapy."

Appeals Process: Internal to External Review

Step-by-Step Appeals Timeline

Step Timeline Action Required Where to Submit
Internal Appeal 180 days from denial Submit appeal letter with additional evidence BCBS member portal or appeals address on denial letter
External Review 180 days from final internal denial File through Ohio External Review System Ohio Department of Insurance
Standard External Review 30 days for decision IRO reviews case independently Assigned automatically by ODI
Expedited External Review 72 hours for decision For urgent medical situations Request expedited status

Ohio External Review Process

Ohio's external review is administered by the Ohio Department of Insurance through independent review organizations (IROs). Key features:

  • No cost to the patient
  • Binding decision on the insurer if overturned
  • Medical experts review clinical evidence
  • Consumer hotline: 1-800-686-1526
Important: You must exhaust internal appeals before requesting external review, except in urgent situations.

Common Denial Reasons & How to Fix Them

Denial Reason How to Overturn Required Documentation
"Not meeting eosinophil criteria" Submit recent lab showing ≥150 cells/μL or historical ≥300 cells/μL Complete blood count with differential from certified lab
"Step therapy not completed" Document medical necessity exception or previous failures Prior authorization forms for failed medications, adverse event reports
"Insufficient trial of standard therapy" Provide detailed medication history with dates and outcomes Pharmacy records, physician notes documenting inadequate response
"Not medically necessary" Submit comprehensive clinical narrative with guideline citations Specialist evaluation, pulmonary function tests, exacerbation history

Clinician Corner: Medical Necessity Letter Checklist

For prescribers writing appeals, include these elements:

✓ Patient identification and diagnosis with ICD-10 codes
✓ Clinical history including onset, severity, and progression
✓ Prior treatments with specific medications, doses, duration, and outcomes
✓ Current clinical status with objective measures (FEV1, eosinophil count, ACT score)
✓ Treatment rationale citing FDA labeling and clinical guidelines
✓ Monitoring plan for safety and efficacy
✓ Prescriber credentials and specialty certification

When Coverage Gets Complex: Counterforce Health Support

Navigating insurance approvals for specialty medications like Nucala can be overwhelming, especially when facing denials or complex prior authorization requirements. Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into successful, evidence-backed appeals.

The platform analyzes denial letters alongside plan policies and clinical notes to identify the specific denial basis—whether it's PA criteria, step therapy requirements, or "not medically necessary" determinations. It then drafts targeted rebuttals using the right evidence, from FDA labeling to peer-reviewed studies, while ensuring all required clinical facts are properly documented.

For Ohio patients dealing with BCBS denials, this type of specialized support can be particularly valuable given the state's robust external review process and the complexity of biologic medication approvals.

FAQ: Ohio-Specific Questions

How long does BCBS prior authorization take in Ohio? Standard PA decisions are typically made within 15 business days. Urgent requests may be expedited to 72 hours. Check your specific plan's member handbook for exact timelines.

What if Nucala is not on my BCBS formulary? You can request a formulary exception by demonstrating medical necessity and failure of formulary alternatives. This requires detailed clinical documentation and often peer-to-peer review.

Can I request an expedited appeal in Ohio? Yes, if a delay would seriously jeopardize your health. Both internal appeals and external reviews offer expedited options with shortened timelines (72 hours for external review).

Does step therapy apply if I failed medications with a previous insurer? Generally yes, but you can request a medical necessity exception by providing documentation of previous failures, including pharmacy records and physician notes from your prior coverage.

Who pays for external review in Ohio? The external review process is free to patients. Your insurance company pays the fee to the independent review organization.

What happens if the external review denies my appeal? While the IRO decision is binding on your insurer, you retain the right to seek other remedies, including legal action or regulatory complaints with the Ohio Department of Insurance.

From Our Advocates

"We've seen Ohio patients successfully overturn BCBS Nucala denials by focusing on comprehensive eosinophil trending data rather than single lab values. One effective approach involved submitting 12 months of eosinophil counts showing persistent elevation despite optimized inhaled therapy, combined with detailed exacerbation logs. The key was demonstrating the eosinophilic phenotype pattern over time, not just meeting a threshold on one test date."

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance policies vary by plan and change frequently. Always verify current requirements with your specific BCBS plan and consult your healthcare provider for medical decisions. For official guidance on Ohio insurance appeals, contact the Ohio Department of Insurance at 1-800-686-1526.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.